<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730064</url>
  </required_header>
  <id_info>
    <org_study_id>7580</org_study_id>
    <nct_id>NCT03730064</nct_id>
  </id_info>
  <brief_title>Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression</brief_title>
  <official_title>Neuroinflammation as a Novel Target to Treat Bipolar Depression: A Pilot PET Study With [11C]PBR-28 and N-Acetyl Cysteine (NAC) Antidepressant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Lan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to understand what causes bipolar disorder and how medications treat bipolar&#xD;
      depression. Particularly, we are looking at the importance of inflammation in the process. If&#xD;
      you participate, you will have two different brain scans (MRI and PET scan). You will also&#xD;
      have an experimental treatment for your depression named N-acetyl cysteine (NAC). The study&#xD;
      is funded by the Columbia University Irving Institute to improve the treatment of bipolar&#xD;
      disorder. Please contact us if you are interested in participating. Up to $600 in&#xD;
      compensation if you are eligible and choose to participate. Up to 6 months of treatment for&#xD;
      depression at no cost to you.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>Six weeks</time_frame>
    <description>Total score will be used; Ranges from 0 to 60 points; 60 is more most severe depression</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Bipolar depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine (NAC)</intervention_name>
    <description>Experimental medication with N-acetyl cysteine (NAC) for six weeks</description>
    <arm_group_label>Bipolar depressed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bipolar 2 disorder and meets criteria for a major depressive episode&#xD;
&#xD;
          -  Age 18-60&#xD;
&#xD;
          -  Females of child-bearing potential must be willing to use an acceptable method of&#xD;
             birth control throughout the study&#xD;
&#xD;
          -  Not currently taking psychotropic medications besides those allowed in the clinical&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failed trial or intolerable side effects of NAC&#xD;
&#xD;
          -  Diagnosis of other major psychiatric disorders such as lifetime schizophrenia,&#xD;
             schizoaffective disorder, psychotic features of bipolar disorder, current drug or&#xD;
             alcohol abuse or recent drug or alcohol dependence&#xD;
&#xD;
          -  Significant active physical illness, including blood dyscrasias, lymphomas,&#xD;
             hypersplenism, endocrinopathies, renal failure, chronic obstructive lung disease,&#xD;
             autonomic neuropathies, peripheral vascular disease. Any disorders with inflammation,&#xD;
             malignancy, autoimmune or infectious etiology. Systolic blood pressure &gt;140 or&#xD;
             diastolic blood pressure &gt; 100 Hemoglobin &lt;11 in females or &lt;13 in males&#xD;
&#xD;
          -  Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel&#xD;
             in the body&#xD;
&#xD;
          -  Current, past or anticipated exposure to radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Martin Lan</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>NAC</keyword>
  <keyword>N-acetyl cysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

